Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study ; volume:13 ; number:1 ; day:11 ; month:11 ; year:2023 ; pages:1-9 ; date:12.2023
Scientific reports ; 13, Heft 1 (11.11.2023), 1-9, 12.2023
- Urheber
-
Congdon, Seth
Narrowe, Zev
Yone, Nang
Gunn, Jacob
Deng, Yuting
Nori, Priya
Cowman, Kelsie
Islam, Marjan
Rikin, Sharon
Starrels, Joanna
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-46912-4
- URN
-
urn:nbn:de:101:1-2024013013064296318511
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Congdon, Seth
- Narrowe, Zev
- Yone, Nang
- Gunn, Jacob
- Deng, Yuting
- Nori, Priya
- Cowman, Kelsie
- Islam, Marjan
- Rikin, Sharon
- Starrels, Joanna
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia
Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia
Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia
Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients